A Phase 2 interventional study of ABX464 in Rheumatoid Arthritis, sponsored by Abivax S.A.. Completed at 14 sites in 4 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 290 studies in Arthritis, Rheumatoid with a site in Poland — 13 open to participants now, 22 under way, 3 of them phase 3. Arthritis, Rheumatoid · Poland.
Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, this one is the 268th largest by enrollment of the 284 interventional ones that give a count, is one of 12 that started in 2019, is one of 141 in phase 2, and was the 240th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →13 of the 290 studies in Arthritis, Rheumatoid with a site in Poland are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Poland, United States, Belgium and 8 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Poland, United States, Brazil
Ages 18+
4th Military Clinical Hospital with Polyclinic, Poland · Sites in Poland
Ages 18+
GlaxoSmithKline · Sites in Poland, Argentina, Brazil and 6 more countries
Ages 18–70
AstraZeneca · Sites in Poland, United States, Argentina and 14 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
290 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 149 · Phase 3 106 · Phase 4 10
First in 2001; this study’s year is marked. 12 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 292 across the 284 interventional studies, 193 across the 6 observational. Of the 267 that completed or were terminated, 196 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
285 of 290 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Rheumatoid with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.
This Phase 2a open-label study aims at investigating the long-term safety and efficacy of an oral dose of ABX464 in patients who have been previously enrolled in the ABX464-301 clinical study and who are willing to continue their treatment.
All patients will receive ABX464 given at 50mg o.d. irrespectively of their previous treatment received in the ABX464-301 study (i.e. ABX464 or Placebo).
The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator's judgement.
Patients will be treated with ABX464 for a period of 52 weeks. If they achieve a clinical response on Week 52 (defined as DAS28-CRP ≤ 2,6 for anti-TNFα naïve patients or DAS-28-CRP ≤ 3,2 for patients previously treated by anti-TNFα), they will be eligible to continue treatment for up to 104 weeks.Patients will be followed up at week , week 2 and then, on a monthly basis the first year (up to W52), and quaterly the second year (up to W104).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Criteria that should be met by patients at week 52 to be eligible for 52 additional weeks of study treatment:
▪ Patients should be in clinical response. Clinical response is defined as: DAS28-CRP ≤ 2,6 for anti-TNFα naïve patients or DAS-28-CRP ≤ 3,2 for patients previously treated by anti-TNFα.
Exclusion Criteria:
All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks)
Drug: ABX464
All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
Incidence of treatment-emergent adverse events in the ABX464 treated Patients, categorized by severity
Incidence of adverse events emerging during the treatment
Time frame: through study completion (average of 104 weeks)
Proportion of patients achieving Low Disease Activity (LDA)
Low Disease Activity (LDA) is defined as DAS28-ESR \<=3.2
Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Proportion of patients achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission
The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1
Time frame: Week 4, Week 12, Week24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Proportion of patients achieving Simplified Disease Activity Score (SDAI) remission
The SDAI remission is considered achieved if the SDAI score ≤ 3.3
Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Proportion of patients achieving Clinical Disease Activity (CDAI) remission
The CDAI remission is considered achieved if the CDAI score ≤ 2.8
Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Proportion of patients achieving ACR20/50/70 response
The categorical American College of Rheumatology 20% or 50% or 70% (ACR20/50/70) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% or 50% or 70% improvement in the ACR response.
Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Proportion of patients achieving categorical Disease Activity Scores (DAS) (measured on 28 joints) - C-Reactive Protein (DAS28-CRP) response
Proportion of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) \[DAS28-CRP\] response will be measured as moderate/good European League Against Rheumatism (EULAR) response
Time frame: Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Time to onset of the Low Disease Activity (LDA) remission
time when DAS28-ESR \<=3.2
Time frame: up to 104 weeks
Time to onset of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission
The ACR/EULAR remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All ≤ 1. Time to onset will be when this criteria will be ≤ 1
Time frame: up to 104 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2019 to primary completion in Jan 2023, 38 months.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 38 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464